• Profile

The "shelf life" of biologics for patients with psoriasis and PsA

JAMA Dermatology May 20, 2022

Why this study matters

Patients with moderate-to-severe PsA who have failed non-biologic therapy are often prescribed biologic agents, including IL-17, TNF, and IL-12/23 inhibitors. This study showed that treatment persistent is short (< 3 years) for all biologics tested and suggest that ongoing treatment of PsA patients may require regular treatment changes.

Study design

A total of 6531 patients (mean age, 49.1 years; 54.6% women) with PsA newly-prescribed biologics from the French health insurance scheme database were enrolled and followed prospectively for continued use of the biologic. A TNF, IL-12/23, and IL-17 inhibitor was prescribed to 76.2%, 12.3%, and 11.5% of the PsA patients, respectively.

Results and conclusion

The 3-year continued biologic agent use (i.e., treatment persistence) among PsA patients was 36.2%. Persistent use of an IL-17 inhibitor was greater than TNF (HR = 0.70) and IL-12/23 inhibitors (HR = 0.69). There was no difference in persistent use between TNF and IL-12/23 inhibitors.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen